...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
【24h】

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.

机译:CYP2C19基因多态性对冠心病患者5毫克普拉格雷,10毫克普拉格雷和75毫克氯吡格雷的药代动力学和药效学的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

CYP2C19 genotype has been shown to impact response to clopidogrel 75-mg but not prasugrel 10-mg. Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and clopidogrel 75-mg using data from two PK/PD studies in stable coronary artery disease (CAD) patients (GENERATIONS and FEATHER). Active metabolite concentrations (area under the curve, AUC[0-tlast]), maximum platelet aggregation (MPA) measured by light transmission aggregometry, vasodilator-stimulated phosphoprotein platelet reactivity index, and VerifyNow P2Y12-platelet reaction units (VN-PRU) were analysed by CYP2C19-predicted phenotype (extensive metaboliser [EM; N=154], *2-*8 non-carriers, vs reduced metaboliser [RM; N=41],*2-*8 carriers/*17 non-carriers). AUC(0-tlast) was unaffected by metaboliser status for prasugrel 5-mg and 10-mg (geometric mean EM/RM ratios 1.00, 95% confidence interval [CI]: 0.86,1.17, p>0.99; and 0.97, 95% CI:0.85,1.12, p=0.71, respectively), but was lower among RMs receiving clopidogrel 75-mg (1.37, 95% CI:1.14,1.65, p<0.001). Platelet reactivity was not significantly affected by CYP2C19 metaboliser status for prasugrel 5-mg, or for prasugrel 10-mg by MPA and VN-PRU, but for clopidogrel 75-mg was significantly higher in reduced metabolisers (all measures p<0.01). Prasugrel 10-mg showed greater antiplatelet effects vs clopidogrel 75-mg (all comparisons p<0.001). Prasugrel 5-mg showed greater antiplatelet effects vs clopidogrel 75-mg in RMs (all p<0.001), and comparable effects in EMs (all p≥0.37). In contrast to clopidogrel, prasugrel active metabolite PK was not influenced by CYP2C19 genotype. Antiplatelet effect for prasugrel 10-mg was greater irrespective of metaboliser status and for prasugrel 5-mg was greater for RMs and comparable for EMs as compared to clopidogrel 75-mg.
机译:CYP2C19基因型已显示对75 mg氯吡格雷的反应有影响,但对prasugrel 10 mg的影响不大。在这里,我们使用两项在稳定冠心病(CAD)中进行的PK / PD研究的数据,评估了CYP2C19代谢状态对prasugrel 5-mg和10-mg和clopidogrel 75-mg的药代动力学(PK)和药效学(PD)反应的影响。患者(GENERATIONS和FEATHER)。活性代谢物浓度(曲线下面积,AUC [0-tlast]),通过光透射聚集法测量的最大血小板聚集(MPA),血管舒张剂刺激的磷蛋白血小板反应性指数和VerifyNow P2Y12-血小板反应单位(VN-PRU)为通过CYP2C19预测的表型进行分析(广泛代谢者[EM; N = 154],* 2- * 8个非携带者,减少的代谢者[RM; N = 41],* 2- * 8个携带者/ * 17个非携带者) 。普拉格雷5 mg和10 mg(几何平均EM / RM比1.00,95%置信区间[CI]:0.86,1.17,p> 0.99;和0.97,95%)的AUC(0-tlast)不受代谢状态的影响CI:0.85,1.12,p = 0.71),但在接受氯吡格雷75 mg的RM中较低(1.37,95%CI:1.14,1.65,p <0.001)。 CYP2C19代谢状态对prasugrel 5-mg或prasugrel 10-mg的MPA和VN-PRU的血小板反应性没有显着影响,但对于75-mg clopidogrel,在减少的代谢物中,其血小板反应性显着更高(所有方法p <0.01)。普拉格雷10 mg的抗血小板作用比氯吡格雷75 mg的抗血小板作用更大(所有比较,p <0.001)。在RMs中,普拉格雷5mg的抗血小板作用高于氯吡格雷75mg(所有p <0.001),而在EMs中的抗血小板作用相似(所有p≥0.37)。与氯吡格雷相反,普拉格雷活性代谢物PK不受CYP2C19基因型的影响。与氯吡格雷75 mg相比,普拉格雷10 mg的抗血小板作用更大,与代谢物状态无关,而对于RM而言普拉格雷5 mg的抗血小板作用更大,对于EM则更是如此。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号